Loading
A phase 3 trial testing Emactuzumab, active and no longer recruiting.
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study is a phase 3 interventional study registered as NCT03768063, led by Hoffmann-La Roche, and active but no longer recruiting on the registry. Official title: An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B). Planned enrolment is 1000 participants (estimated). The study started in 2019-02-28 and primary completion is expected in 2028-07-05. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/